Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ebos GroupASX:EBO -1.85%74 EV-to-EBIT is 13.34 as of Jul. 30, 2026, which is 20% below its 10-year median of 16.73. GuruFocus rates ASX:EBO with a GF Score™ of 74/100 and a GF Value™ of A$31.61 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 94 Medical Distribution companies, Ebos Group ranks worse than 60.64% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Ebos Group's Enterprise Value for the quarter that ended in Dec. 2025 was A$6,407 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ebos Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$398 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ebos Group EV-to-EBIT Related Terms
Ebos Group EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Ebos Group's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Ebos Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ebos Group EV-to-EBIT vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Ebos Group's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Ebos Group's EV-to-EBIT falls into.
Ebos Group's current Enterprise Value is A$5,307 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ebos Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$398 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ebos Group (ASX:EBO) has a EV-to-EBIT of 13.34 as of Jul. 30, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Ebos Group and its competitors. This is 20% below median its historical median of 16.73. Over the past decade, Ebos Group's EV-to-EBIT has ranged from 12.77 to 26.51. According to the industry distribution chart, Ebos Group ranks #57 out of 94 companies in the Medical Distribution industry, placing it in the top 60.6%.
Is Ebos Group's EV-to-EBIT too high?
Ebos Group's current EV-to-EBIT of 13.34 is 20% below median its 10-year median of 16.73. Over the past 10 years, this metric has ranged from a low of 12.77 to a high of 26.51. The Medical Distribution industry median EV-to-EBIT is 11.78. Ebos Group's value of 13.34 is 13.3% above this industry median. Based on the distribution chart, Ebos Group ranks #57 out of 94 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Ebos Group has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ebos Group's EV-to-EBIT compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Ebos Group ranks #57 out of 94 companies for EV-to-EBIT. This places Ebos Group in the lower half of its industry. The industry median EV-to-EBIT is 11.78. Ebos Group's value of 13.34 is 13.3% above this benchmark. Historically, Ebos Group's own EV-to-EBIT has ranged from 12.77 to 26.51 over the past decade. While the company's 10-year median is 16.73 vs. the industry median of 11.78, Ebos Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Distribution company?
The median EV-to-EBIT among Medical Distribution companies is 11.78, based on 94 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ebos Group's current EV-to-EBIT of 13.34 is 13.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Ebos Group and its competitors. For the Medical Distribution industry, the median EV-to-EBIT is 11.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ebos Group's current EV-to-EBIT is 13.34, which is 20% below median its own 10-year median of 16.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ebos Group stock overvalued right now?
Based on GuruFocus' analysis, Ebos Group (ASX:EBO) is currently considered Significantly Undervalued. The stock's GF Value™ is A$31.61, compared to a current price of A$18.53 — trading 41.4% below its estimated fair value. The current EV-to-EBIT is 13.34, which is 20% below median its 10-year median of 16.73 and 13.3% above the Medical Distribution industry median of 11.78. Ebos Group's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Ebos Group (ASX:EBO), the current EV-to-EBIT is 13.34 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ebos Group (ASX:EBO) Overvalued in 2026?
Based on GuruFocus' analysis, Ebos Group stock appears to be undervalued.
The current stock price of A$18.53 is trading 41.4% below its estimated GF Value™ of A$31.61.
GuruFocus considers Ebos Group to be Significantly Undervalued.
Key valuation signals for ASX:EBO:
EV-to-EBIT: 13.34 (20% below median its 10-year median of 16.73)
GF Value™: A$31.61 vs. price of A$18.53 (41.4% below fair value)
Industry Position: 13.3% above the Medical Distribution median (#57 of 94)
No single metric tells the full story. See the ASX:EBO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ebos is the largest pharmaceutical wholesaler across Australia and New Zealand. It services community pharmacies and hospitals, which contribute around 50% and 30% of revenue, respectively. Drug pricing and wholesale margins for PBS medicine are governed by the Australian government's Pharmaceutical Benefits Scheme, or PBS. Wholesale gross margins are capped at 7% for community pharmacy and 10% for hospitals, and ongoing price reform typically results in low-single-digit revenue growth. Aside from pharma distribution, Ebos operates an animal health product wholesale, manufacturing and retail business, as well as undertaking third party logistics services. These segments are smaller contributors to group revenue but due to the unregulated nature are higher-margin operations.
74GF Score
Get the complete analysis for ASX:EBO
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:EBO has been successfully added to your 
